Cingulate (CING) announced that the positive Phase 3 results from its pivotal trial of CTx-1301 in pediatric ADHD, were recently presented by Ann Childress, M.D., at the AACAP Annual Meeting in Chicago. CTx-1301 met its primary endpoint, demonstrating dose-dependent improvements on the ADHD ratings scale 5, and Clinical Global Impression-Severity scales, and demonstrated the ability to deliver symptom relief with the convenience of once-daily dosing.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success
- Cingulate price target raised to $17 from $10 at Roth Capital
- Cingulate Inc’s NDA for CTx-1301 Accepted by FDA
- Cingulate announces FDA accepted for review the NDA for CTx-1301
- Cingulate Inc Approves Stock Issuance Proposal